The blood-based analysis of circulating tumor cells or tumor derived nucleic acids is referred to as “liquid biopsy”. It is a non-invasive way of diagnosing or monitoring a tumor disease, or treatment response. The main target of this analysis is cell-free DNA (cfDNA), which is released into the blood stream by necrotic and apoptotic cells. Elevated levels of cfDNA are found in patients with cancer and other types of diseases.
Since only a small fraction of the circulating DNA is derived from the tumor (ctDNA), highly sensitive detection methods, as for example digital droplet PCR (ddPCR), or next generation sequencing (NGS), are advantageous. Whereas ddPCR allows detecting a specific mutation with the highest sensitivity possible, NGS based analysis has the potential to provide a more complete genetic signature of the patient’s entire tumor burden.
CeGaT’s sequencing and digital PCR services offer reliable and accurate insights into different types of liquid biopsies, from nucleic acid extraction to tailored data analysis.
With our long-standing expertise in the diagnostic field, our clients benefit from strict quality control standards and, therefore, high quality results.